Terms: = Bone cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Clinical Outcome
14 results:
1. LncRNA LINC00467 contributes to osteosarcoma growth and metastasis through regulating HMGA1 by directly targeting miR-217.
Ma HZ; Wang J; Shi J; Zhang W; Zhou DS
Eur Rev Med Pharmacol Sci; 2020 Jun; 24(11):5933-5945. PubMed ID: 32572906
[TBL] [Abstract] [Full Text] [Related]
2. Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: A bone marrow pathology group study.
Rogers HJ; Wang X; Xie Y; Davis AR; Thakral B; Wang SA; Borthakur G; Cantu MD; Margolskee EM; Philip JKS; Sukhanova M; Bagg A; Bueso-Ramos CE; Orazi A; Arber DA; Hsi ED; Hasserjian RP
Am J Hematol; 2020 Jul; 95(7):799-808. PubMed ID: 32249963
[TBL] [Abstract] [Full Text] [Related]
3. Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.
Hemming ML; Lawlor MA; Zeid R; Lesluyes T; Fletcher JA; Raut CP; Sicinska ET; Chibon F; Armstrong SA; Demetri GD; Bradner JE
Proc Natl Acad Sci U S A; 2018 Jun; 115(25):E5746-E5755. PubMed ID: 29866822
[TBL] [Abstract] [Full Text] [Related]
4. Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia.
Strickland SA; Shaver AC; Byrne M; Daber RD; Ferrell PB; Head DR; Mohan SR; Mosse CA; Moyo TK; Stricker TP; Vnencak-Jones C; Savona MR; Seegmiller AC
Leuk Res; 2018 Feb; 65():67-73. PubMed ID: 29310020
[TBL] [Abstract] [Full Text] [Related]
5. Metformin reduces SATB2-mediated osteosarcoma stem cell-like phenotype and tumor growth via inhibition of N-cadherin/NF-kB signaling.
Xu HY; Fang W; Huang ZW; Lu JC; Wang YQ; Tang QL; Song GH; Kang Y; Zhu XJ; Zou CY; Yang HL; Shen JN; Wang J
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4516-4528. PubMed ID: 29131265
[TBL] [Abstract] [Full Text] [Related]
6. Significance of kit exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia.
Jang W; Yoon JH; Park J; Lee GD; Kim J; Kwon A; Choi H; Han K; Nahm CH; Kim HJ; Min WS; Kim M; Kim Y
Blood Cancer J; 2016 Jan; 6(1):e387. PubMed ID: 26771813
[TBL] [Abstract] [Full Text] [Related]
7. TERT promoter mutations in sinonasal malignant melanoma: a study of 49 cases.
Jangard M; Zebary A; Ragnarsson-Olding B; Hansson J
Melanoma Res; 2015 Jun; 25(3):185-8. PubMed ID: 25746036
[TBL] [Abstract] [Full Text] [Related]
8. [Clinicopathologic features and prognostic factors of malignant phyllodes tumors].
Jia C; Mei F; Zheng J; You JF; Liu JY
Zhonghua Bing Li Xue Za Zhi; 2013 Nov; 42(11):729-34. PubMed ID: 24447548
[TBL] [Abstract] [Full Text] [Related]
9. Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma.
Chang DZ; Ma Y; Ji B; Wang H; Deng D; Liu Y; Abbruzzese JL; Liu YJ; Logsdon CD; Hwu P
Clin Cancer Res; 2011 Nov; 17(22):7015-23. PubMed ID: 21976550
[TBL] [Abstract] [Full Text] [Related]
10. Impact of platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and disseminated tumor cells in bone marrow of ovarian cancer patients.
Wimberger P; Roth C; Pantel K; Kasimir-Bauer S; Kimmig R; Schwarzenbach H
Int J Cancer; 2011 Jun; 128(11):2572-80. PubMed ID: 20715113
[TBL] [Abstract] [Full Text] [Related]
11. Primary intradural chordoma: report on three cases and review of the literature.
Bergmann M; Abdalla Y; Neubauer U; Schildhaus HU; Probst-Cousin S
Clin Neuropathol; 2010; 29(3):169-76. PubMed ID: 20423692
[TBL] [Abstract] [Full Text] [Related]
12. Sarcomas and pharmacogenetics.
Biason P; Toffoli G
Pharmacogenomics; 2005 Sep; 6(6):585-601. PubMed ID: 16142999
[TBL] [Abstract] [Full Text] [Related]
13. Levels of the soluble, 55-kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence.
Wu S; Korte A; Gessner R; Henze G; Seeger K
Cancer; 2003 Aug; 98(3):625-31. PubMed ID: 12879482
[TBL] [Abstract] [Full Text] [Related]
14. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
Scotlandi K; Manara MC; Strammiello R; Landuzzi L; Benini S; Perdichizzi S; Serra M; Astolfi A; Nicoletti G; Lollini PL; Bertoni F; Nanni P; Picci P
J Clin Oncol; 2003 May; 21(10):1952-60. PubMed ID: 12743148
[TBL] [Abstract] [Full Text] [Related]
